


Searching News Database: neurodegenerative disease
HSMN NewsFeed - 2 Oct 2025
OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates
OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates
HSMN NewsFeed - 19 May 2025
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(R) for ALS
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(R) for ALS
HSMN NewsFeed - 4 Apr 2025
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
HSMN NewsFeed - 20 Jun 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
HSMN NewsFeed - 17 Jun 2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
HSMN NewsFeed - 24 Oct 2023
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
HSMN NewsFeed - 7 Mar 2023
Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer
Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 31 Aug 2022
iQure Pharma Secures $600K in Early Closing to Research Neuropathic Pain Therapies
iQure Pharma Secures $600K in Early Closing to Research Neuropathic Pain Therapies
HSMN NewsFeed - 27 Jul 2022
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
HSMN NewsFeed - 15 Jun 2022
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
HSMN NewsFeed - 30 Mar 2022
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 22 Feb 2022
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
HSMN NewsFeed - 22 Jun 2021
Valeo Pharma Announces Commercial Launch of Enerzair(R) Breezhaler(R) and Atectura(R) Breezhaler(R)
Valeo Pharma Announces Commercial Launch of Enerzair(R) Breezhaler(R) and Atectura(R) Breezhaler(R)
HSMN NewsFeed - 15 Apr 2021
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
HSMN NewsFeed - 11 Jan 2021
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
HSMN NewsFeed - 9 Dec 2020
Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)
Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)
HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
HSMN NewsFeed - 12 Nov 2020
Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium
Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 26 Aug 2020
MedGenome announces Strategic Collaboration in Parkinson's Disease with Denali Therapeutics
MedGenome announces Strategic Collaboration in Parkinson's Disease with Denali Therapeutics
HSMN NewsFeed - 24 Aug 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
HSMN NewsFeed - 3 Feb 2020
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 26 Aug 2019
Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
HSMN NewsFeed - 4 Jun 2019
Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
HSMN NewsFeed - 1 May 2019
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
HSMN NewsFeed - 11 Mar 2019
Alcyone Lifesciences Receives Breakthrough Device Designation from U.S. FDA for the ThecaFlex DRx(TM) System
Alcyone Lifesciences Receives Breakthrough Device Designation from U.S. FDA for the ThecaFlex DRx(TM) System
HSMN NewsFeed - 22 Feb 2019
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
HSMN NewsFeed - 30 Aug 2018
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
HSMN NewsFeed - 23 Aug 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
HSMN NewsFeed - 13 Jun 2018
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
HSMN NewsFeed - 1 Jun 2018
Fortuna Fix Announces Appointment of Madhavan Balachandran to Board of Directors
Fortuna Fix Announces Appointment of Madhavan Balachandran to Board of Directors
HSMN NewsFeed - 26 Apr 2018
Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)
Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)
HSMN NewsFeed - 8 Mar 2018
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
HSMN NewsFeed - 11 Jan 2018
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
HSMN NewsFeed - 4 Dec 2017
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
HSMN NewsFeed - 27 Nov 2017
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
HSMN NewsFeed - 2 Nov 2017
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
HSMN NewsFeed - 12 Jul 2017
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
HSMN NewsFeed - 11 Jul 2017
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
HSMN NewsFeed - 27 Jun 2017
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
HSMN NewsFeed - 11 Apr 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
HSMN NewsFeed - 28 Nov 2016
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 14 Jul 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
HSMN NewsFeed - 19 Jan 2016
Amylyx Announces Election of Nobel Laureate Walter Gilbert, PhD, to Board of Directors
Amylyx Announces Election of Nobel Laureate Walter Gilbert, PhD, to Board of Directors
HSMN NewsFeed - 2 Dec 2015
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
HSMN NewsFeed - 2 Sep 2015
Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing
Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing
HSMN NewsFeed - 23 Jul 2015
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing
HSMN NewsFeed - 23 Oct 2014
AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. as Chief Executive Officer
AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 30 Jun 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
HSMN NewsFeed - 25 Mar 2014
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
HSMN NewsFeed - 13 Feb 2014
MYOS Corporation Announces Appointment of Robert C. Ashton, Jr., M.D., as Chief Medical Officer
MYOS Corporation Announces Appointment of Robert C. Ashton, Jr., M.D., as Chief Medical Officer
HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
HSMN NewsFeed - 31 Dec 2013
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
HSMN NewsFeed - 18 Oct 2013
Celladon Corporation Appoints Michael Narachi as Chairman of the Board of Directors
Celladon Corporation Appoints Michael Narachi as Chairman of the Board of Directors
HSMN NewsFeed - 13 Sep 2013
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
HSMN NewsFeed - 10 Sep 2013
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
HSMN NewsFeed - 7 May 2013
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
HSMN NewsFeed - 13 Feb 2013
Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development
Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development
HSMN NewsFeed - 28 Jan 2013
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
HSMN NewsFeed - 30 Jan 2012
Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
HSMN NewsFeed - 16 Feb 2011
sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
HSMN NewsFeed - 24 Jan 2011
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
HSMN NewsFeed - 4 Oct 2010
Genzyme Board Urges Shareholders to Take No Action On sanofi-aventis’ Unsolicited Tender Offer
Genzyme Board Urges Shareholders to Take No Action On sanofi-aventis’ Unsolicited Tender Offer
HSMN NewsFeed - 11 Aug 2010
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
HSMN NewsFeed - 8 Jun 2010
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
HSMN NewsFeed - 7 Jun 2010
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
HSMN NewsFeed - 24 May 2010
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
HSMN NewsFeed - 26 Mar 2010
Cortex Sells Selected AMPAKINE Compounds and Rights to Respiratory Depression Indication to Biovail
Cortex Sells Selected AMPAKINE Compounds and Rights to Respiratory Depression Indication to Biovail
HSMN NewsFeed - 8 Jan 2010
Industry Veteran Ron Branning Joins Genzyme to Lead Global Product Quality
Industry Veteran Ron Branning Joins Genzyme to Lead Global Product Quality
HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
HSMN NewsFeed - 21 Oct 2009
Wellstat Therapeutics and sanofi-aventis Enter Agreement on Novel Therapy for Type II Diabetes
Wellstat Therapeutics and sanofi-aventis Enter Agreement on Novel Therapy for Type II Diabetes
HSMN NewsFeed - 7 Oct 2009
Epizyme Closes $32 Million Series B Financing, Led by New Investor Bay City Capital
Epizyme Closes $32 Million Series B Financing, Led by New Investor Bay City Capital
HSMN NewsFeed - 10 Sep 2009
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
HSMN NewsFeed - 24 Aug 2009
Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera
Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera
HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 19 Mar 2009
Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease
Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease
HSMN NewsFeed - 18 Mar 2009
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 19 Feb 2009
QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
HSMN NewsFeed - 8 Jan 2009
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
HSMN NewsFeed - 18 Dec 2008
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
HSMN NewsFeed - 12 Sep 2008
Power3 Medical Products, Inc. Appoints Helen Park as Interim Chief Executive Officer
Power3 Medical Products, Inc. Appoints Helen Park as Interim Chief Executive Officer
HSMN NewsFeed - 15 Aug 2008
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
HSMN NewsFeed - 10 Jun 2008
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
HSMN NewsFeed - 9 Jun 2008
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Merck Announces Planned Investment of $50 Million in Research Center in the US
HSMN NewsFeed - 3 Mar 2008
Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform
Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform
HSMN NewsFeed - 12 Nov 2007
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
HSMN NewsFeed - 12 Oct 2007
Elekta: Finding Hope for Autism - New Brain Research Technology Centre Opened by HRH Princess Anne
Elekta: Finding Hope for Autism - New Brain Research Technology Centre Opened by HRH Princess Anne
HSMN NewsFeed - 10 Oct 2007
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
HSMN NewsFeed - 8 Oct 2007
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
HSMN NewsFeed - 7 Sep 2007
RXi Pharmaceuticals Names Life Science Veteran Stephen J. DiPalma Chief Financial Officer
RXi Pharmaceuticals Names Life Science Veteran Stephen J. DiPalma Chief Financial Officer
HSMN NewsFeed - 28 Aug 2007
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 27 Jun 2007
CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
HSMN NewsFeed - 22 May 2007
CytRx Names Shi Chung Ng, Ph.D., Senior Vice President of Research and Development
CytRx Names Shi Chung Ng, Ph.D., Senior Vice President of Research and Development
HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
HSMN NewsFeed - 2 May 2007
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 8 Mar 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
HSMN NewsFeed - 20 Feb 2007
Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co., Inc.
Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co., Inc.
HSMN NewsFeed - 22 Jan 2007
Isis Announces Appointment of Jeffrey M. Jonas, M.D. as Executive Vice President
Isis Announces Appointment of Jeffrey M. Jonas, M.D. as Executive Vice President
HSMN NewsFeed - 19 Jan 2007
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
HSMN NewsFeed - 10 Jan 2007
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
HSMN NewsFeed - 9 Jan 2007
Stem Cell Innovations Announces Issuance of Fundamental Human Stem Cell Patent
Stem Cell Innovations Announces Issuance of Fundamental Human Stem Cell Patent
HSMN NewsFeed - 4 Jan 2007
ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery
ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
HSMN NewsFeed - 4 Dec 2006
New Atlanta-Based Pharmaceutical Company Focuses on Central Nervous System
New Atlanta-Based Pharmaceutical Company Focuses on Central Nervous System
HSMN NewsFeed - 6 Nov 2006
Pharmacopeia Announces the Appointment of Vice President, Clinical and Regulatory Affairs
Pharmacopeia Announces the Appointment of Vice President, Clinical and Regulatory Affairs
HSMN NewsFeed - 11 Oct 2006
Osta Announces Promising Clinical Results on Blood Tests for Parkinson's Disease & Alzheimer's Disease
Osta Announces Promising Clinical Results on Blood Tests for Parkinson's Disease & Alzheimer's Disease
HSMN NewsFeed - 28 Sep 2006
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Additional items found! 110
Members Archive contains
110 additional stories matching:
neurodegenerative disease
(Password required)
neurodegenerative disease
(Password required)
